ANEB Anebulo Pharmaceuticals
- 1.650
- -0.040-2.37%
Anebulo Pharmaceuticals News
Benchmark Co. Maintains Anebulo Pharmaceuticals(ANEB.US) With Buy Rating, Maintains Target Price $8
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals | 10-K: FY2024 Annual Report
Express News | Anebulo Pharmaceuticals, Inc. Q4 Operating Expenses USD 1.3 Million
Anebulo Pharmaceuticals 4Q Loss/Shr 5c >ANEB
Express News | Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Top Premarket Decliners
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
After-Market Stock Rise In Anebulo (ANEB) Indicates Potential Shift In Investor Sentiment
Express News | Anebulo Pharmaceuticals Awarded Nida Grant for Its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Express News | Lifecore Biomedical: 22Nw Will Withdraw Notice of Nominations of Director Candidates at 2023 Annual Meeting
Express News | Lifecore Biomedical Inc - 22Nw Signs Standstill and Support Agreement
Express News | Lifecore Biomedical Inc - to Add Four Directors to Board
Express News | Lifecore Biomedical Announces Cooperation Agreement With 22Nw
12 Health Care Stocks Moving In Friday's Intraday Session
Anebulo Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Anebulo Pharmaceuticals Q3 EPS $(0.06) Beats $(0.12) Estimate
Anebulo Pharmaceuticals 3Q Loss/Shr 6c >ANEB
Press Release: Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Analysis
Price Target
No Data
No Data